Andrew R Green

Summary

Affiliation: University of Nottingham
Country: UK

Publications

  1. ncbi High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer
    Suet F Chin
    Breast Cancer Functional Genomics, Cancer Research UK Cambridge Research Institute and Department of Oncology University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
    Genome Biol 8:R215. 2007
  2. ncbi MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype
    Cherie Blenkiron
    Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
    Genome Biol 8:R214. 2007
  3. ncbi Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer
    Mark R Pickard
    Institute for Science and Technology in Medicine and School of Life Sciences, Keele University, Huxley Building, Keele ST5 5BG, UK
    Breast Cancer Res 11:R60. 2009
  4. ncbi The prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome
    Andrew R Green
    Division of Pathology, School of Molecular Medical Sciences, Nottingham University Hospitals NHS and University of Nottingham, Nottingham, UK
    Breast Cancer Res Treat 110:427-37. 2008
  5. ncbi Loss of expression of chromosome 16q genes DPEP1 and CTCF in lobular carcinoma in situ of the breast
    Andrew R Green
    Division of Pathology, School of Molecular Medical Sciences, University of Nottingham and Nottingham University Hospitals NHS Trust, Queen s Medical Centre, Nottingham, UK NG7 2UH
    Breast Cancer Res Treat 113:59-66. 2009
  6. ncbi The expression of ERalpha, ERbeta and PR in lobular carcinoma in situ of the breast determined using laser microdissection and real-time PCR
    Andrew R Green
    Division of Pathology, School of Molecular Medical Sciences, University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, UK
    Histopathology 54:419-27. 2009
  7. ncbi PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis
    Mohammed A Aleskandarany
    Division of Pathology, School of Molecular Medical Sciences, University of Nottingham, Queen s Medical Centre, Clifton Boulevard, Nottingham NG7 2UH, UK
    Breast Cancer Res Treat 122:45-53. 2010
  8. ncbi Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen
    Hany Onsy Habashy
    Department of Histopathology, School of Molecular Medical Sciences, University of Nottingham, Nottingham City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK
    Breast Cancer Res Treat 119:283-93. 2010
  9. ncbi RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype
    Hany Onsy Habashy
    Department of Pathology, School of Molecular Medical Sciences, Nottingham University Hospitals NHS Trust, University of Nottingham, Nottingham, UK
    Breast Cancer Res Treat 128:315-26. 2011
  10. ncbi Growth fraction as a predictor of response to chemotherapy in node-negative breast cancer
    Mohammed A Aleskandarany
    Division of Pathology, School of Molecular Medical Sciences, University of Nottingham, Nottingham, United Kingdom
    Int J Cancer 126:1761-9. 2010

Collaborators

Detail Information

Publications56

  1. ncbi High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer
    Suet F Chin
    Breast Cancer Functional Genomics, Cancer Research UK Cambridge Research Institute and Department of Oncology University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
    Genome Biol 8:R215. 2007
    ..To date, most genome-wide array comparative genomic hybridization studies have used tumor panels of relatively large tumor size and high Nottingham Prognostic Index (NPI) that are not as representative of breast cancer demographics...
  2. ncbi MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype
    Cherie Blenkiron
    Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
    Genome Biol 8:R214. 2007
    ..MicroRNAs (miRNAs), a class of short non-coding RNAs found in many plants and animals, often act post-transcriptionally to inhibit gene expression...
  3. ncbi Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer
    Mark R Pickard
    Institute for Science and Technology in Medicine and School of Life Sciences, Keele University, Huxley Building, Keele ST5 5BG, UK
    Breast Cancer Res 11:R60. 2009
    ..Fau modifies apoptosis-controller Bcl-G, which is also a key target for candidate oncoprotein maternal embryonic leucine zipper kinase (MELK)...
  4. ncbi The prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome
    Andrew R Green
    Division of Pathology, School of Molecular Medical Sciences, Nottingham University Hospitals NHS and University of Nottingham, Nottingham, UK
    Breast Cancer Res Treat 110:427-37. 2008
    ..The aims were to identify whether their expression was related to patient outcome, their relationships to known prognostic factors and to provide a basis for further research into the mechanistic significance of such associations...
  5. ncbi Loss of expression of chromosome 16q genes DPEP1 and CTCF in lobular carcinoma in situ of the breast
    Andrew R Green
    Division of Pathology, School of Molecular Medical Sciences, University of Nottingham and Nottingham University Hospitals NHS Trust, Queen s Medical Centre, Nottingham, UK NG7 2UH
    Breast Cancer Res Treat 113:59-66. 2009
    ..The aim of this study is to assess the expression of these genes in LCIS and compare them with normal breast, using CDH1 as a control, in order to evaluate their role as TSGs...
  6. ncbi The expression of ERalpha, ERbeta and PR in lobular carcinoma in situ of the breast determined using laser microdissection and real-time PCR
    Andrew R Green
    Division of Pathology, School of Molecular Medical Sciences, University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, UK
    Histopathology 54:419-27. 2009
    ..To determine the status of oestrogen receptor (ER) subtypes (ERalpha and ERbeta) in lobular carcinoma in situ (LCIS) of the breast...
  7. ncbi PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis
    Mohammed A Aleskandarany
    Division of Pathology, School of Molecular Medical Sciences, University of Nottingham, Queen s Medical Centre, Clifton Boulevard, Nottingham NG7 2UH, UK
    Breast Cancer Res Treat 122:45-53. 2010
    ..Thus, targeting of PIK3CA using specific inhibitors could potentially be beneficial, particularly for patients with more aggressive poorly differentiated tumors, irrespective of their molecular subtype...
  8. ncbi Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen
    Hany Onsy Habashy
    Department of Histopathology, School of Molecular Medical Sciences, University of Nottingham, Nottingham City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK
    Breast Cancer Res Treat 119:283-93. 2010
    ..CD71 appears to be a candidate marker of a subgroup of ER+/luminal-like breast cancer characterised by poor outcome and resistance to tamoxifen...
  9. ncbi RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype
    Hany Onsy Habashy
    Department of Pathology, School of Molecular Medical Sciences, Nottingham University Hospitals NHS Trust, University of Nottingham, Nottingham, UK
    Breast Cancer Res Treat 128:315-26. 2011
    ..In conclusion, we used novel bioinformatics methods to identify candidate genes to characterise ER+ luminal-like breast cancer. RERG gene is a key marker of the luminal BC class and can be used to separate distinct prognostic subgroups...
  10. ncbi Growth fraction as a predictor of response to chemotherapy in node-negative breast cancer
    Mohammed A Aleskandarany
    Division of Pathology, School of Molecular Medical Sciences, University of Nottingham, Nottingham, United Kingdom
    Int J Cancer 126:1761-9. 2010
    ..Patients with a high growth fraction appear to be ideal candidates for adjuvant chemotherapy while those with low growth fraction are less likely to benefit and are prone to the potential serious side effects of adjuvant chemotherapy...
  11. ncbi The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype
    Hany Onsy Habashy
    Department of Histopathology, School of Molecular Medical Sciences, Nottingham University Hospitals NHS Trust, University of Nottingham, Hucknall Road, Nottingham, UK
    Breast Cancer Res Treat 120:603-12. 2010
    ..PELP1 appears to have a potential application in assessing the clinical outcome of patients with ER-positive breast cancer...
  12. ncbi Loss of Dicer expression is associated with breast cancer progression and recurrence
    Sarkawt M Khoshnaw
    Department of Histopathology, School of Molecular Medical Sciences, University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham NG7 2UH, UK
    Breast Cancer Res Treat 135:403-13. 2012
    ..This study provides evidence that Dicer protein plays a role in human BC progression and behaviour, and assessment of its expression could provide prognostic information in BC including the HER2-positive class...
  13. ncbi Calpastatin is associated with lymphovascular invasion in breast cancer
    Sarah J Storr
    Academic Oncology, University of Nottingham, School of Molecular Medical Sciences, Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham NG5 1PB, UK
    Breast 20:413-8. 2011
    ..014 and p=0.025 respectively). The data supports the hypothesis that calpastatin may play a role in regulating the initial metastatic dissemination of breast cancer...
  14. ncbi Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes
    Emad A Rakha
    Department of Histopathology, School of Molecular Medical Sciences, Nottingham University Hospitals NHS Trust, University of Nottingham, Nottingham, UK
    Eur J Cancer 44:73-83. 2008
    ..It is less common than invasive ductal carcinoma (IDC) and few large studies have addressed its biologic characteristics and behaviour with respect to long-term clinical outcome and response to adjuvant therapy...
  15. ncbi Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification
    Desmond G Powe
    Department of Cellular Pathology, Queen s Medical Centre, Nottingham University Hospitals NHS Trust, Derby Road, Nottingham NG7 2UH, UK
    Breast Cancer Res 11:R90. 2009
    ....
  16. ncbi Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype
    Emad A Rakha
    Department of Histopathology and Surgery, School of Molecular Medical Sciences, Nottingham University Hospitals National Health Service Trust and University of Nottingham, Nottingham, United Kingdom
    J Clin Oncol 25:4772-8. 2007
    ..It is usually easier to decide treatment strategies in cases of double-positive/-negative phenotypes than in single-positive tumors...
  17. ncbi Histological grading of breast cancer on needle core biopsy: the role of immunohistochemical assessment of proliferation
    T ng Chang Kwok
    Department of Pathology and School Molecular Medical Sciences, Nottingham University Hospital, Hucknall Road, Nottingham, UK
    Histopathology 57:212-9. 2010
    ..35 and 0.65). A major cause of the discrepancy is underestimation of mitoses in the NCB specimen. The aim was to determine the best method of assessing proliferation on NCB...
  18. ncbi CTEN (C-terminal tensin-like), a novel oncogene overexpressed in invasive breast carcinoma of poor prognosis
    Abdulkader Albasri
    Division of Pathology, School of Molecular Medical Sciences, Queen s Medical Centre, University of Nottingham, Nottingham, UK
    Breast Cancer Res Treat 126:47-54. 2011
    ..In conclusion, our results demonstrated the oncogenetic role of increased CTEN expression and its association with poor prognostic parameters. These data could help in prognostic assessment in BC patients...
  19. ncbi Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
    Mohammed A Aleskandarany
    Department of Histopathology, School of Molecular Medical Sciences, Queens Medical Centre, University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, NG7 2UH, UK
    Breast Cancer Res 14:R3. 2012
    ..This study aimed to assess the prognostic value of a proliferation assay by using Ki-67 immunohistochemistry as compared with mitotic count scores...
  20. ncbi Fatty acid binding protein 7 expression and its sub-cellular localization in breast cancer
    Alaa T Alshareeda
    Department of Histopathology and School of Molecular Medical Sciences, The University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Nottingham, UK
    Breast Cancer Res Treat 134:519-29. 2012
    ..Further investigation of the biology of FABP7 in breast cancer is warranted...
  21. ncbi Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance
    Rabab A A Mohammed
    Department of Clinical Oncology, School of Molecular Medical Sciences, University of Nottingham, Nottingham, UK
    Mod Pathol 24:774-85. 2011
    ..Vascular invasion was, in all phenotypes, almost entirely lymphatic vessel invasion and could stratify basal-like and triple-negative phenotypes into distinct prognostic groups...
  22. ncbi Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer
    Tarek M A Abdel-Fatah
    Division of Pathology, School of Molecular Medical Sciences and Nottingham University Hospitals Trust, University of Nottingham, Nottingham, UK
    J Pathol 222:388-99. 2010
    ....
  23. ncbi A CD44⁻/CD24⁺ phenotype is a poor prognostic marker in early invasive breast cancer
    Mohamed A H Ahmed
    Division of Pathology, School of Molecular Medical Sciences, University of Nottingham, Nottingham, UK
    Breast Cancer Res Treat 133:979-95. 2012
    ..This shows that the relationship between basic cell biology and clinical behaviour is not always straightforward and warrants further investigations of the true clinical impact of breast cancer stem cells...
  24. ncbi EpCAM expression is an indicator of recurrence in basal-like breast cancer
    Ayodeji J Agboola
    Division of Pathology, School of Molecular Medical Sciences, University of Nottingham, Queen s Medical Centre, Nottingham, UK
    Breast Cancer Res Treat 133:575-82. 2012
    ..97, P = 0.005) and MFS (LR 4.01, P = 0.045). EpCAM may play a role in breast cancer progression and its expression is associated with poor patient outcome in basal-like breast cancer, independent of other prognostic factors...
  25. ncbi FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer
    Hany Onsy Habashy
    School of Molecular Medical Sciences, University of Nottingham, Nottingham, NG7 2UH, UK
    Breast Cancer Res Treat 129:11-21. 2011
    ..In conclusion, our results demonstrate the biological and prognostic role of FOXO3a protein expression and its subcellular localisation in ER-positive/luminal-like BC possibly through its involvement in controlling cell proliferation...
  26. ncbi The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers
    Tarek M Abdel-Fatah
    Division of Pathology, School of Molecular Medical Sciences, Nottingham University Hospitals NHS Trust, UK
    J Pathol 220:419-34. 2010
    ....
  27. ncbi Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer
    Mohammed A Aleskandarany
    Division of Pathology, School of Molecular Medical Sciences, Queen s Medical Centre, University of Nottingham, Nottingham, UK
    Breast Cancer Res Treat 127:407-16. 2011
    ..These findings may help development more adequate therapeutic regimens for specific subgroups of this key cancer pathway...
  28. ncbi A review of the biological and clinical characteristics of luminal-like oestrogen receptor-positive breast cancer
    Hany O Habashy
    Division of Pathology, School of Molecular Medical Sciences, University of Nottingham, Nottingham, UK
    Histopathology 60:854-63. 2012
    ..In this review, we explore the concept and definitions of the luminal-like class of breast carcinoma and their contribution to our understanding of their molecular features, clinical significance and therapeutic implications...
  29. ncbi An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer
    Sahar M A Mahmoud
    Division of Pathology, School of Molecular Medical Sciences, University of Nottingham, Queen s Medical Centre, Nottingham, NG7 2UH, UK
    Breast Cancer Res Treat 127:99-108. 2011
    ..We therefore conclude that FOXP3(+) infiltrating cells do not have a dominant role in breast cancer prognosis and suggest that other inflammatory cell subsets may be more critical variables...
  30. ncbi Lymph-node metastases in invasive lobular carcinoma are different from those in ductal carcinoma of the breast
    Beatriz Fernández
    Departments of Histopathology and Surgery, Nottingham University Hospitals NHS Trust, The University of Nottingham, Nottingham, UK
    J Clin Pathol 64:995-1000. 2011
    ..The pattern of nodal metastatic deposits (nodular, sinusoidal and diffuse) and the proportion of involved nodes were also analysed in a selected group of 246 tumours, which were associated with a single positive ALN...
  31. ncbi A methodology to identify consensus classes from clustering algorithms applied to immunohistochemical data from breast cancer patients
    Daniele Soria
    School of Computer Science, University of Nottingham, Jubilee Campus, Wollaton Road, Nottingham, UK
    Comput Biol Med 40:318-30. 2010
    ..We apply the methodology to immunohistochemical data from breast cancer patients. In doing so, we identify six core classes, of which several may be novel sub-groups not previously emphasised in literature...
  32. ncbi Detection and quantification of microRNAs in laser-microdissected formalin-fixed paraffin-embedded breast cancer tissues
    Sarkawt M Khoshnaw
    Department of Histopathology, School of Molecular Medical Sciences, University of Nottingham and Nottingham University Hospitals Trust, Nottingham, UK
    Methods Mol Biol 755:119-42. 2011
    ..In this chapter, techniques for the analysis of miRNA expression in laser-microdissected formalin-fixed paraffin-embedded breast cancer tissues are discussed...
  33. ncbi MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups
    Mohammed A Aleskandarany
    Division of Pathology, School of Molecular Medical Sciences, Queen s Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK
    Breast Cancer Res Treat 127:591-9. 2011
    ....
  34. ncbi The microRNA maturation regulator Drosha is an independent predictor of outcome in breast cancer patients
    Sarkawt M Khoshnaw
    Department of Histopathology, School of Molecular Medical Sciences, University of Nottingham, Nottingham, UK
    Breast Cancer Res Treat 137:139-53. 2013
    ..These observations provide further evidence that alterations in miRNA regulation influence tumour behaviour...
  35. ncbi TOMM34 expression in early invasive breast cancer: a biomarker associated with poor outcome
    Mohammed A Aleskandarany
    Division of Pathology, School of Molecular Medical Sciences, University of Nottingham, Nottingham, United Kingdom
    Breast Cancer Res Treat 136:419-27. 2012
    ..Our findings underscore the role played by mitochondrial machinery in BC progression and warrant their validation on a prospective basis...
  36. ncbi Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments
    Fabrício F T Barros
    School of Molecular Medical Sciences, University of Nottingham, Nottingham, NG7 2UH, UK
    Histopathology 56:560-72. 2010
    ..The study of interaction between receptors/ligands will characterize specifically their signalling pathway and understand which strategy to acquire...
  37. ncbi CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome
    Somaia Elsheikh
    Department of Histopathology, School of Molecular Medical Sciences, Nottingham City Hospital NHS Trust, University of Nottingham and University Hospitals NHS Trust, Nottingham, UK
    Breast Cancer Res Treat 109:325-35. 2008
    ....
  38. ncbi Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival
    Desmond G Powe
    Department of Cellular Pathology, Queen s Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham, NG7 2UH, UK
    Oncotarget 1:628-38. 2010
    ..A larger epidemiological study leading to randomised clinical trials is needed for breast and other cancer types including colon, prostate and ovary...
  39. ncbi Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome
    Somaia E Elsheikh
    Department of Histopathology, School of Molecular Medical Sciences, University of Nottingham and Nottingham Universities Hospital Trust, University of Nottingham, Nottingham, United Kingdom
    Cancer Res 69:3802-9. 2009
    ..This study identifies the presence of variations in global levels of histone marks in different grades, morphologic types, and phenotype classes of invasive breast cancer and shows that these differences have clinical significance...
  40. ncbi Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast
    Emad A Rakha
    Department of Histopathology, School of Molecular Medical Sciences, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, NG5 1PB, UK
    Breast Cancer Res Treat 111:121-7. 2008
    ..As it is less common than invasive ductal carcinoma, few studies of large size have addressed the value of assessment of histologic grade in ILC...
  41. ncbi Improved methods of detection of lymphovascular invasion demonstrate that it is the predominant method of vascular invasion in breast cancer and has important clinical consequences
    Rabab A A Mohammed
    Clinical Oncology, University of Nottingham, University Hospitals, City Hospital Campus, Nottingham, UK
    Am J Surg Pathol 31:1825-33. 2007
    ..The use of immunohistochemical staining with a lymphendothelial specific marker such as podoplanin/D2-40 increases the accuracy of identification of patients with tumor associated LVI...
  42. ncbi Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer
    Sahar M A Mahmoud
    School of Molecular Medical Sciences and School of Community Health Sciences, University of Nottingham, Nottingham, United Kingdom
    J Clin Oncol 29:1949-55. 2011
    ..These results suggest that tumor-infiltrating CD8(+) T lymphocytes have antitumor activity as judged by their favorable effect on patients' survival and could potentially be exploited in the treatment of breast cancer...
  43. ncbi FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis
    Somaia Elbauomy Elsheikh
    Department of Histopathology, School of Molecular Medical Sciences, Queen s Medical Centre, Nottingham University Hospitals Trust and University of Nottingham, Nottingham, UK
    Breast Cancer Res 9:R23. 2007
    ..Recent studies have demonstrated that specific FGFR1 amplification correlates with gene expression and that FGFR1 activity is required for the survival of a FGFR1 amplified breast cancer cell line...
  44. ncbi Calpain-1 expression is associated with relapse-free survival in breast cancer patients treated with trastuzumab following adjuvant chemotherapy
    Sarah J Storr
    Academic Oncology, University of Nottingham, School of Molecular Medical Sciences, Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham, United Kingdom
    Int J Cancer 129:1773-80. 2011
    ..05-20.25; p = 0.043). Calpain-1 may be a useful biomarker to predict relapse-free survival in breast cancer patients treated with adjuvant trastuzumab and chemotherapy. A larger verification study is warranted...
  45. ncbi The cadherin switch in ovarian high-grade serous carcinoma is associated with disease progression
    Livia Quattrocchi
    Department of Histopathology, Nottingham University Hospitals NHS Trust, Queen s Medical Centre Campus, Nottingham, NG7 2UH, UK
    Virchows Arch 459:21-9. 2011
    ..Our results indicate that the cadherin switch alters through progression of HGSC. The profile of combined cadherin expressions in association with survival raises expectations in targeted therapy...
  46. ncbi Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients
    Nicholas F S Watson
    Academic Department of Clinical Oncology, University of Nottingham, City Hospital, Nottingham, United Kingdom
    Int J Cancer 118:1445-52. 2006
    ..In contrast, patients with high expression of MICA may be candidates for the antibody therapies, as they should be susceptible to NK killing by antibody dependent cellular cytotoxicity...
  47. ncbi Prognostic markers in triple-negative breast cancer
    Emad A Rakha
    Department of Histopathology, Molecular Medical Sciences, University of Nottingham, Nottingham, United Kingdom
    Cancer 109:25-32. 2007
    ..Triple-negative breast cancer (estrogen receptor-negative, progesterone receptor-negative, and HER2-negative) is a high risk breast cancer that lacks the benefit of specific therapy that targets these proteins...
  48. ncbi Comparison of the PharmDx immunohistochemical system with standard methods for assessing estrogen and progesterone receptors in invasive carcinoma of the breast
    M Shaffiq Gill
    Department of Histopathology, Nottingham University Hospitals, Nottingham NG5 1PB, UK
    Appl Immunohistochem Mol Morphol 21:90-3. 2013
    ..This study aimed to compare immunohistochemistry for these markers using the pharmDx system and standard methods...
  49. ncbi Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer
    Emad A Rakha
    Department of Histopathology, The Breast Unit, Nottingham City Hospital, University of Nottingham, Nottingham, UK
    Mod Pathol 18:1295-304. 2005
    ..In conclusion, most breast carcinomas express MUC1, MUC3 and MUC4. Among the various mucins expressed in breast cancer, MUC1 and MUC3 are potential prognostic indicators, MUC1 having the strongest relationship with patient outcome...
  50. ncbi Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance
    Emad A Rakha
    Molecular Medical Sciences, University of Nottingham and Department of Histopathology and Surgery, Nottingham City Hospital NHS Trust, Hucknall Road, Nottingham, NG5 1PB, UK
    Eur J Cancer 42:3149-56. 2006
    ..These are important observations as these tumours typically lack hormone receptor and HER-2 overexpression limiting the range of relevant adjuvant therapies...
  51. ncbi Expression of BRCA1 protein in breast cancer and its prognostic significance
    Emad A Rakha
    Department of Histopathology, The Breast Unit, Nottingham City Hospital, University of Nottingham, NG5 1PB Nottingham, UK
    Hum Pathol 39:857-65. 2008
    ..Immunohistochemical assessment of BRCA1 expression could provide additional clinically relevant information in routine classification of breast cancer...
  52. ncbi The collagen receptor Endo180 (CD280) Is expressed on basal-like breast tumor cells and promotes tumor growth in vivo
    Dirk Wienke
    Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom
    Cancer Res 67:10230-40. 2007
    ..Together, these data argue that elevated expression of this receptor in tumor cells could have important consequences in subsets of basal-like carcinomas for which there is a current lack of effective treatment...
  53. ncbi Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients
    Abeer M Shaaban
    YCR and Liz Dawn Pathology and Translational Sciences Centre, Leeds Teaching Hospitals and Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom
    Clin Cancer Res 14:5228-35. 2008
    ..Our aim was to elucidate the prognostic significance of ERbeta1, ERbeta2, and ERbeta5 by immunohistochemistry in a large cohort of breast carcinomas with long-term follow-up...
  54. ncbi Breast carcinoma with basal phenotype: mammographic findings
    Angela A Luck
    Nottingham International Breast Education Centre, Nottingham City Hospital, Hucknall Rd, Nottingham NG5 1PB, United Kingdom
    AJR Am J Roentgenol 191:346-51. 2008
    ..Basal phenotype has been found to be an independent poor prognostic factor for breast cancer. The aim of this study was to assess the mammographic appearance of screening-detected breast carcinoma with the basal phenotype...
  55. ncbi Neonatal tamoxifen treatment of mice leads to adenomyosis but not uterine cancer
    Andrew R Green
    MRC Molecular Endocrinology Group, Reproductive Sciences Section, University of Leicester, Robert Kilpatrick Building, Leicester LE2 7LX, UK
    Exp Toxicol Pathol 56:255-63. 2005
    ..Results provide a basis for understanding the mechanism for tamoxifen induced tissue remodelling and the development of adenomyosis...
  56. ncbi Chromosome 16 tumor-suppressor genes in breast cancer
    Emad A Rakha
    Department of Histopathology, The Breast Unit, Nottingham City Hospital NHS Trust and University of Nottingham, Nottingham, United Kingdom
    Genes Chromosomes Cancer 45:527-35. 2006
    ..This review discusses the complexity of the 16q region and the different approaches that have been, are being, and will be used to detect the target genes in this area...